Skip to content

Celldex Therapeutics, Inc.

CLDX· Nasdaqxbrl foundCIK 744218

In vitro & in vivo diagnostic substances19 peers

Last sale
Nov 12, 2026 · -5.46%
Market cap
$2.24B
78.55M shares
Filings
1,030
$37.00K
Q3 2026−78.0% FY25 yoy
-$75.56M
Q3 2026N/M FY25 yoy
-$82.25M
Q3 2026N/M FY25 yoy
-$194.52M
Q3 2026derivedN/M FY25 yoy
-$0.96
Q3 2026N/M FY25 yoy
$26.95M
Q3 2026+1.8% FY25 yoy
$2.24B
—
14172.9×
3.4×
-11.60%
—

Twelve months to Sep 30, 2026 · derived

Price

$28.51+16.99%+$4.14past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of record

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$1.55MFY 2025
$12.74M0FY 2014FY 2019FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$1,545,000reported
FY 20242024-12-31$7,020,000reported
FY 20232023-12-31$6,883,000reported
FY 20222022-12-31$2,357,000reported
FY 20212021-12-31$4,651,000reported
FY 20202020-12-31$7,418,000reported
FY 20192019-12-31$3,573,000reported
FY 20182018-12-31$9,538,000reported
FY 20172017-12-31$12,743,000reported
FY 20162016-12-31$6,786,000reported
FY 20152015-12-31$5,480,000reported
FY 20142014-12-31$3,586,000reported

Segments

Products
Revenue by Products, FY2018 to FY2024FY2018Contracts and grants · FY2018 · $6.20MProduct development and licensing agreements · FY2018 · $3.34MFY2019Contracts and grants · FY2019 · $3.10MProduct development and licensing agreements · FY2019 · $473.00KFY2020Contracts and grants · FY2020 · $5.12MProduct development and licensing agreements · FY2020 · $2.30MFY2021Contracts and grants · FY2021 · $4.62MProduct development and licensing agreements · FY2021 · $31.00KFY2022Contracts and grants · FY2022 · $2.30MProduct development and licensing agreements · FY2022 · $56.00KFY2023Contracts and grants · FY2023 · $6.61MProduct development and licensing agreements · FY2023 · $278.00KFY2024Contracts and grants · FY2024 · $7.01MProduct development and licensing agreements · FY2024 · $13.00K
LineFY2024ShareChange
Contracts and grants$7.01M100%+6.1%
Product development and licensing agreements$13.00K0.2%−95.3%
Total$7.02M

From the 10-K filed Feb 27, 2025CLDX

In vitro & in vivo diagnostic substances

Celldex Therapeutics, Inc. is the 14th largest of the 20 covered companies the SEC files under this code, by revenue. SIC 2835

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Celldex Therapeutics, Inc. · CIK 744218 · Engraved from SEC EDGAR